Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Abrahamsson

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Leukemia|October 16, 2019
T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocolP Quist-Paulsen, N Toft, M Heyman, et al.
Leukemia|December 16, 2018
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemiaS Modvig, H O Madsen, S M Siitonen, et al.
Leukemia|December 12, 2019
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemiaS Modvig, H O Madsen, S M Siitonen, et al.
Leukemia|December 15, 2020
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter settingS Modvig, H Hallböök, H O Madsen, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Leukemia|October 16, 2019
T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocolP Quist-Paulsen, N Toft, M Heyman, et al.
Leukemia|December 16, 2018
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemiaS Modvig, H O Madsen, S M Siitonen, et al.
Leukemia|December 12, 2019
Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemiaS Modvig, H O Madsen, S M Siitonen, et al.
Leukemia|December 15, 2020
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter settingS Modvig, H Hallböök, H O Madsen, et al.
Pageof 5